BYRYZN in Daegu — where it sits between filler and skin booster
“Is BYRYZN a filler or a skin booster?” Its ingredient is the same cross-linked hyaluronic acid as a filler, but the depth, amount and aim are different. It is also the only class among Miso Clinic’s boosters that can be dissolved and reversed.
The short answer
BYRYZN is not a filler that fills volume but a skin booster that places cross-linked hyaluronic acid shallowly in the dermis, in small divided amounts, to address texture, fine lines and hydration. The one human study naming the product is a single-arm pilot of 20 people, three sessions two weeks apart, 12 weeks: the wrinkle scale fell by about 40% at week 8 and about 33% was maintained at week 12, but there was no control group. Sagging and major volume loss are not this product’s territory, and the biggest difference from other boosters is that it can be broken down with hyaluronidase if a problem arises.
Is BYRYZN a filler or a skin booster?
By ingredient it belongs with fillers; by the way it is used it is a skin booster. BYRYZN Skinbooster HA is an injectable of cross-linked hyaluronic acid gel mixed with 0.3% lidocaine. In Korea it is a medical device (tissue-restoration biomaterial) with the indication “temporary improvement of facial wrinkles in adults”. It is a Hugel brand, manufactured by the affiliate ACROSS.
| Item | HA filler | BYRYZN | Non-cross-linked HA (hydration injections) |
|---|---|---|---|
| Cross-linking | Yes | Yes (manufacturer: degree of cross-linking reduced) | No |
| How it is placed | Builds volume in one area | Small amounts at many points, shallow in the dermis | Many points, shallow in the dermis |
| Aim | Volume · contour | Texture · fine lines · hydration | Hydration |
| Breakdown | Slow | Slower than non-cross-linked | Fast — needs frequent repeats |
| Reversal | Possible with hyaluronidase | Possible with hyaluronidase | Not applicable |
The manufacturer’s “minimal cross-linking” and “minimal Tyndall effect” are manufacturer descriptions without independently verified data. We also could not find the hyaluronic acid concentration or the type and degree of cross-linker in public sources.
What the 20-person study established, and what it did not
BYRYZN is one of the few boosters with a human study published under its own product name. Researchers at Yonsei Severance published it in J Cosmet Dermatol in 2024.
| Item | Detail |
|---|---|
| Design | Prospective · single centre · single-arm pilot (the authors call it a pilot study) |
| Subjects | 20 people aged 30–60, mean 54.1 |
| Method | Three intradermal injections two weeks apart, 12 weeks of follow-up |
| Wrinkles | Lemperle scale 2.60 ± 0.60 → week 8 1.55 ± 0.51 (about a 40% reduction), about 33% maintained at week 12 |
| Safety | No serious adverse events; transient subcutaneous nodule in one person |
- With no control group, it is impossible to separate how much of the change came from the product
- Twenty people are too few to catch rare side effects
- There are no data beyond 12 weeks, so we do not say “lasts so many months”
- There is no study comparing it directly with other skin boosters
What it means that it can be reversed
Of the seven boosters Miso Clinic stocks, BYRYZN is the only one that hyaluronidase can break down. CaHA (DCLASSY · Radiesse) has no dissolving agent, and PCL (GOURI), PN (Rejuran) and hADM (Re2O · CellREDM) likewise leave you waiting for time to pass once injected.
So for someone having a booster for the first time, or unsure how the result will turn out, starting with a reversible material is a reasonable choice. Hyaluronidase itself can cause allergic reactions, though, and it also breaks down the hyaluronic acid that was already there, so it should be understood as a safeguard if a problem arises, not as “just dissolve it and that’s that”.
Lasting longer also means a poor placement lasts longer. Placed too shallowly it can show through as a bluish tint (the Tyndall effect), so with this product the depth of injection decides the result more than the amount.
Skin BYRYZN suits, and skin it does not
| Situation | Judgement | Why |
|---|---|---|
| Rough texture, inner tightness and dullness are the main complaint | Consider first | Places a water-binding material directly |
| Hydration injections wore off too quickly | Consider | Cross-linking slows breakdown |
| First booster, and you want to start with a reversible material | Consider | Can be broken down with hyaluronidase |
| Sagging jawline or cheeks is the main problem | Not recommended | Injections do not lift — lifting devices |
| Major volume loss | Not recommended | Skin booster amounts are not meant to fill |
| You want the skin itself to become thicker | Another class | Classes that stimulate collagen, or hADM that supplies material |
If you have had an adverse reaction to a hyaluronic acid product before, or are allergic to lidocaine, tell us before treatment. We do not treat during pregnancy or breastfeeding, as there are no study data.
Summary
What is established
- Cross-linked hyaluronic acid + 0.3% lidocaine; tissue-restoration biomaterial in Korea — indication temporary improvement of facial wrinkles
- One human study naming the product: 20 people · three sessions · 12 weeks, wrinkles about 40% lower at week 8 (no control group)
- Can be broken down with hyaluronidase — the only one of Miso Clinic’s seven boosters
What we could not find
- How long results last beyond 12 weeks
- A controlled study, or a direct comparison with other skin boosters
- Hyaluronic acid concentration, degree of cross-linking, and the licence number in the original record
BYRYZN in Daegu: frequently asked questions
How is BYRYZN different from hydration injections?
The ingredient is the same hyaluronic acid; the difference is cross-linking. Ordinary hydration injections are non-cross-linked and break down quickly, so they are repeated often; BYRYZN is cross-linked and breaks down more slowly. In return, the depth at which it is placed matters more.
How long does BYRYZN last?
What the published study confirmed runs to 12 weeks, and a large part of the week-8 improvement was maintained at week 12. There are no data after that, so we do not give a number of months.
How many BYRYZN sessions do I need?
The study used three sessions two weeks apart, but that is not evidence that everyone needs that number. Miso Clinic recommends one session, then adjusting after seeing the response.
Can BYRYZN be dissolved?
Yes. It can be broken down with hyaluronidase. Hyaluronidase can itself cause allergic reactions, though, and also breaks down the hyaluronic acid already present in the area, so it is more accurate to think of it as a safeguard.
Should I have BYRYZN or Rejuran first?
To address texture and hydration relatively quickly, we consider BYRYZN; to address the recovery environment of skin that has become thin and reactive, Rejuran. No study compares the two directly, and they are less competitors than treatments with different jobs.
Can BYRYZN show through as a bluish tint?
If placed too shallowly it can cause the Tyndall effect, which shows most in thin areas such as under the eyes. What decides this is injection depth more than the product, and even if it happens it can be reversed with hyaluronidase.
Read next
Product pages
The product itself is covered in the BYRYZN reference; the seven classes are compared in Collagen boosters compared.
Who wrote this
Written and reviewed by Lee Chi-Hak, MD, medical director of Miso Clinic in Daegu, South Korea. Every study cited above is given together with its design, its size and the limitations the authors themselves recorded, and where we could not find data, we have said that we could not find any.
| Medical director | Lee Chi-Hak, MD |
|---|---|
| Address | 4F Bombom Building, 125 Dongdeok-ro, Jung-gu, Daegu, South Korea · Exit 1, Kyungpook National University Hospital Station |
| Phone | +82-53-428-2700 |
| Hours | Weekdays 11:00–19:00 (lunch 13:00–14:00) / Saturday 10:00–16:00 (no lunch break) / Closed Sundays and public holidays |
| Columns | All clinical columns |
| Reference library | All booster and device references |
References
- BYRYZN human study — Lee JH et al., J Cosmet Dermatol 2024;23(2):409–416, DOI 10.1111/jocd.15944. Prospective · single centre · single-arm pilot, 20 subjects (mean age 54.1), three intradermal injections two weeks apart, 12 weeks of follow-up. Lemperle wrinkle scale 2.60 ± 0.60 → week 8 1.55 ± 0.51 (about a 40% reduction), about 33% maintained at week 12. Transient subcutaneous nodule in one person. No control group.
- BYRYZN product information — Hugel brand, manufactured by ACROSS. Cross-linked hyaluronic acid + 0.3% lidocaine, two 1.1 mL syringes (carton labelling). Medical device (tissue-restoration biomaterial); indication “temporary improvement of facial wrinkles in adults”. We could not find the product licence number in public sources; the 62026-I10-23-2790 on promotional material is a medical advertising pre-review number.
- Medical advertising law — Korea’s Medical Service Act, Article 56(2). It prohibits advertising through treatment testimonials, comparison with other medical institutions, superlative claims and similar.
- Miso Clinic clinical protocols — criteria for indications, design by area, and the explanation and consent process before treatment. The source of the sentences marked “clinical judgement” in this column.
Everything in this column is general information and does not replace medical diagnosis or treatment. Effects and side effects vary with individual skin condition, age and underlying illness, and the same result is not guaranteed for everyone. Any decision to proceed should be made in an in-person consultation with a physician.